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Abstract Amyloidosis is a disease characterized by depo-
sitions of amyloid in organs and tissues. It can be localized
(in just one organ) or systemic. Cardiac amyloidosis is a
debilitating disease and can lead to arrhythmias, deteriora-
tion of heart function and even sudden death. We reviewed
PubMed/Medline, without time constraints, on the different
nuclear imaging modalities that are used to visualize
myocardial amyloid involvement. Several SPECT tracers
have been used for this purpose. The results with these
tracers in the evaluation of myocardial amyloidosis and
their mechanisms of action are described. Most clinical
evidence was found for the use of 123I-MIBG. Myocardial
defects in MIBG activity seem to correlate well with
impaired cardiac sympathetic nerve endings due to amyloid
deposits. 123I-MIBG is an attractive option for objective
evaluation of cardiac sympathetic level and may play an
important role in the indirect measurement of the effect of
amyloid myocardial infiltration. Other, less sensitive,
options are 99mTc-aprotinin for imaging amyloid deposits
and perhaps 99mTc-labelled phosphate derivatives, especial-
ly in the differential diagnosis of the aetiology of cardiac
amyloidosis. PET tracers, despite the advantage of absolute
quantification and higher resolution, are not yet well
evaluated for the study of cardiac amyloidosis. Because of
these advantages, there is still the need for further research
in this field.
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Introduction
Amyloidosis is a disease characterized by extracellular
tissue deposition of fibrils composed of low molecular
weight subunits of a variety of serum proteins (amyloid).
Deposition of amyloid can be localized (restricted to one
organ or site of the body) or systemic (in various organs
and tissues throughout the body). Clinical manifestations
are based on the site of the amyloid deposits and are related
to the type of precursor protein involved. Systemic
amyloidosis is usually fatal and is the cause of about 1
per 1,000 deaths in developed countries. About 3,000 new
cases are diagnosed annually in the United States, but
amyloidosis is probably underdiagnosed in the elderly
population.
Cardiac amyloidosis is described as involvement of the
heart by amyloid deposition, whether as part of systemic
amyloidosis (as is most commonly the case) or as a
localized phenomenon [1]. This can lead to severe
arrhythmias, a quick deterioration of heart function, or
even sudden death. Several imaging modalities have been
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used to diagnose and identify the extent of amyloid
deposition in the heart. No single modality has evolved
into a “gold standard”. Diagnostic imaging of the severity
of the cardiac amyloidosis is important and valuable in the
decision making concerning implantable cardioverter defi-
brillator (ICD) implants or heart transplantation and risk
criteria prior to liver transplantation (LT), especially in the
hereditary form of amyloidosis (ATTR) caused by a
mutation of the precursor protein transthyretin (TTR).
Therefore, reliable early detection and measurement of
cardiac involvement are invaluable.
We performed a bibliometric search on MEDLINE
(PubMed) to evaluate the different imaging modalities used
to visualize myocardial amyloid involvement (see Methods).
In a recent review, Selvanayagam et al. described nonnuclear
imaging modalities. Echocardiography may show several
features that are suggestive of cardiac amyloidosis such as
thickening of the left ventricular (LV) wall, increased
echogenicity of the myocardium, reduced systolic function,
thickened valves and a small pericardial effusion. However,
the classical features are commonly present only in the later
stages of disease. Typical findings on the electrocardiogram
are low voltages and a pseudoinfarct pattern, neither of
which are very specific for cardiac amyloidosis. Cardiovas-
cular magnetic resonance imaging may offer promise for the
early detection of cardiac involvement using the late
gadolinium enhancement technique, but this has yet to be
proved [1].
Specifically we concentrated on the nuclear imaging
modalities, because of their ability to identify pathophysio-
logical activity. This makes it possible to identify organs at
risk at an early stage before structural changes have occurred.
Nuclear imaging modalities have also the value of reproduc-
ible quantification and can even monitor whether therapy is
successful. In addition to reviewing the literature, we also
wanted to identify the optimal imaging regime to identify
amyloidosis patients at risk of cardiac involvement.
Amyloid subtypes
There are several subtypes of amyloidosis based on the type
of protein involved and/or the aetiology for the formation of
protein fibrils. Four major systemic types of amyloidosis
have been identified [2]:
1. AA type amyloidosis may complicate chronic inflamma-
tory diseases. Serum amyloid A protein, an acute phase
reactant, is the precursor protein. Most frequently
observed (about 90%) are renal manifestations (protein-
uria and renal failure. Less frequently seen are autonomic
neuropathy, hepatomegaly and cardiomyopathy.
2. AL type amyloidosis develops due to deposition of
protein derived from immunoglobulin light chain frag-
ments produced by a plasma cell dyscrasia. Clinical
manifestations are very diverse and depend on the
severity of deposition in the various organs and tissues.
3. ATTR type amyloidosis may be hereditary or age-
related (senile). The hereditary form is caused by an
autosomal-dominant mutation of the precursor protein
TTR. More than 80 mutations have been described.
Prominent clinical manifestations are peripheral and
autonomic neuropathy, but cardiomyopathy and renal
failure have also been observed. Severe cardiomyopa-
thy may be the presenting sign in some of the TTR
mutations. In the very old, normal TTR can also behave
as precursor protein (‘wild-type’). This occurs in 25%
of patients over the age of 80 years and is characterized
by a slowly progressive cardiomyopathy.
4. Aβ2M type amyloidosis. Patients with chronic renal
failure and haemodialysis for a long time may suffer from
a decreased clearance and deposition ofβ2-microglobulin
in bones and joints.
Beside these four major groups several other types have
been discovered [3] (see Table 1).
Cardiac amyloidosis
Cardiac morbidity is based on several pathophysiological
mechanisms which occur as a consequence of myocardial
deposits of amyloid. Large amounts of deposits may lead to
myocyte dysfunction, which is a result of a mechanical
obstruction. This may lead to systolic or diastolic dysfunc-
tion and symptoms of heart failure. Deposits in the
conduction system can lead to dysrhythmias as a result of
neuronal dysfunction and to syncope due to arrhythmia or
even heart block.
Infiltration of amyloid in the atria as well as the
ventricles may cause atrial dysfunction and electromechan-
ical dysfunction of the atrial electrical activity (e.g. atrial
fibrillation). This may predispose to thromboembolism.
Accumulation of amyloid in the coronary arteries may
explain the manifestation of angina or infarction. Cardiac
involvement is predominantly present in AL type amyloid-
osis. Up to 50% of patients suffer from cardiac manifes-
tations and 25% show congestive heart failure [4]. Atrial
fibrillation and conduction abnormalities are also common.
Cardiac involvement is less common in AA type amyloid-
osis. Less than 5% of patients with this type have cardiac
involvement [5]. In ATTR type amyloidosis cardiac
involvement is as frequent as in AL type but leads more
rarely to LV systolic dysfunction and clinical congestive
heart failure. Problems that occur are cardiac denervation,
diastolic dysfunction and atrioventricular block. The prob-
lems associated with ATTR types vary with the specific
mutation variant [6]. Some mutations are invariably
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associated with cardiac disease, others usually only with
neurological disease, and many a combination of both. The
senile form often has cardiac involvement and is related
with congestive heart failure and conduction abnormalities.
Cardiac involvement in AL type amyloidosis often leads
to significant rapidly progressive cardiac dysfunction, while
the ATTR types are typically associated with milder clinical
manifestations and slower progression [7].
Methods
For collecting imaging studies we used MEDLINE
(PubMed) to search the literature using the following
search terms ‘myocard*’ AND ‘amyloid*’ AND ‘imaging’.
This produced 114 results. These results were manually
scanned and articles were excluded based on the following
criteria: amyloid was not the main topic, but only an
example; ‘amyloid’ and ‘myocard’ were unrelated in the
article; language other than English, German or Dutch. This
resulted in 55 studies of a nuclear imaging modality.
In addition, for every imaging modality a search was
performed with the terms ‘myocard*’ AND ‘amyloid*’
AND ‘name of the imaging modality’. This resulted in a
further seven articles. In total, we found 62 studies (59
SPECT, 3 PET). The SPECT studies were classified based
on the physiological mechanism that was visualized (see
Table 2). Finally, each imaging modality was reviewed in
terms of its results.
Table 2 Nuclear imaging modalities for cardiac amyloidosis









Ventricular function Radionuclide ventriculography (3)
Table 1 Amyloid types
Amyloid type Protein precursor Systemic (S)/Localized (L) Clinical features
AA Serum amyloid A S Reactive; renal failure, proteinuria,
hepatomegaly, neuropathy, cardiomyopathy (<5%)
AL Immunoglobulin
light chain
S, L Plasma cell dyscrasia; all kinds of manifestations,
cardiomyopathy (26–50%)
ATTR Transthyretin S Hereditary or age-related (senile); neuropathy,
cardiomyopathy, renal failure
Aβ2M β2-Microglobulin S After chronic dialysis; bone and joint problems
AH Immunoglobulin
heavy chain
S, L Plasma cell dyscrasia; all kinds of manifestations
AApoAI Apolipoprotein AI S, L Hereditary; neuropathy, nephropathy, aorta (local)
AApoAII Apolipoprotein AII S Hereditary
AApoAIV Apolipoprotein AIV S Sporadic, associated with ageing
AGel Gelsolin S Hereditary
ACys Cystatin C S Hereditary; cerebral haemorrhage
ALys Lysozyme S Hereditary
AFib Fibrinogen S Hereditary, renal failure
ABri ABriPP S Familial dementia, British
ADan ADanPP L Familial dementia, Danish
Aβ Aβ protein precursor L Alzheimer’s disease, ageing
ACal (Pro)calcitonin L Medullary carcinomas of the thyroid
AANF Atrial natriuretic factor L Isolated atrial amyloid
AIAPP Islet amyloid polypeptide L Islet of Langerhans, diabetes type II, insulinoma
APrP Prion protein L Spongiform encephalopathies
APro Prolactin L Ageing pituitary, prolactinomas
AIns Insulin L Iatrogenic
AMed Lactadherin L Senile aortic, media
AKer Kerato-epithelin L Cornea, familial
ALac Lactoferrin L Cornea




At present, the most commonly used SPECT tracer to
assess cardiac neurotransmission is 123I-MIBG [8]. It is
widely accepted as a good method for assessing myocardial
sympathetic nerve activity and innervation in a variety of
cardiac disease states and the effect of treatment with
cardiovascular drugs in chronic heart failure [9].
MIBG (metaiodobenzylguanidine) is an analogue of the
“false” neurotransmitter guanetidine, a potent neuron-
blocking agent that acts selectively on sympathetic nerves.
MIBG has a molecular structure similar to that of
noradrenaline and shares the same uptake and storage
mechanisms in the sympathetic nerve endings [8].
On the other hand, in contrast to noradrenaline, MIBG
undergoes almost no metabolism via enzymes. So MIBG is
retained in the sympathetic nerve endings and the localiza-
tion of MIBG relates to the presence of sympathetic nerves.
When labelled with 123I, it can be used to image the
sympathetic nervous system in various organs, and has an
important role in myocardial imaging [10].
The most common indices are the heart to mediastinum
(H/M) ratio and the washout rate obtained from anterior
planar images. Early images are obtained 15 to 30 min after
injection, delayed images 4 h later (see Fig. 1). The
accumulation on the early MIBG image reflects the
distribution of cardiac sympathetic nerves and the uptake
function at the nerve endings, while the washout rate is an
index of the degree of sympatheticotonia. The rate of
uptake of MIBG in the myocardium is as low as 1–2%. It is
possible to obtain a mean value for the whole LV, but also
for the various regions by analysis on a polar map.
The use of MIBG in patients with amyloidosis was
reported for the first time by Nakata et al. in 1995, who
found decreased myocardial activity of 123I-MIBG in all
cardiac regions in a patient with severe peripheral neurop-
athy due to a TTR-related familial amyloidotic polyneur-
opathy (FAP). Nakata et al. were the first to suggest the
Fig. 1 MIBG uptake in the
heart after 15 min (left) and
after 4 h (right). The H/M ratio
was 3.06 after 15 min and 2.65
after 4 h. The washout was 13%
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hypothesis that a myocardial defect of MIBG activity
provides direct evidence of impaired cardiac sympathetic
nerve endings due to amyloid deposits in FAP [11]. This
finding was confirmed by Arbab et al. in 1997, who also
reported almost no uptake of 123I-MIBG in the heart of a
man with FAP. This patient underwent several investiga-
tions. 99mTc (V)-DMSA showed some myocardial involve-
ment of amyloidosis, and 201Tl and 123I-BMIPP showed
normal blood perfusion and normal fatty acid metabolism,
respectively (all these tracers are discussed below in this
review). The decreased uptake of MIBG in the heart
indicated a severe impairment of sympathetic function [12].
In 1997, Tanaka et al. were the first to perform a
prospective study to assess myocardial sympathetic inner-
vation using 123I-MIBG imaging in patients with FAP and
compared it with other imaging modalities. They performed
echocardiography, 123I-MIBG, 201Tl and 99mTc-PYP (dis-
cussed below) imaging of the heart in 12 patients with FAP
and biopsy-proven cardiac amyloidosis. LV wall thickening
on echocardiography was observed in 4 of 10 patients who
had no clinical evidence of overt heart disease. Eight of the
12 patients showed no myocardial MIBG accumulation,
with limited uptake in the remaining 4 only in the LV
anterior wall. Diffuse but mild uptake of 99mTc-PYP
occurred in only 4 of the 12 patients, and all 12 had
normal results on 201Tl scanning. They concluded that
patients with FAP show a high incidence of myocardial
denervation with viable myocardium that can be identified
in early stage cardiac amyloidosis [13].
Another clinical trial was performed by Delahaye et al.
who studied 17 patients with biopsy-proven FAP by 123I-
MIBG, heart rate variability analysis, coronary angiogra-
phy, radionuclide ventriculography, rest 201Tl SPECT and
echocardiography. Coronary arteries, LV systolic function
and rest 201Tl studies were normal in all patients. On
echocardiographic examination evidence of only mild
amyloid infiltration was found. Cardiac MIBG uptake was
dramatically decreased in patients compared with age-
matched control subjects (H/M ratio at 4 h: 1.36±0.26 vs.
1.98±0.35, p<0.001). There was no difference in washout
rate. The clinical severity of the polyneuropathy correlated
with the decrease in MIBG uptake at 4 h. So patients with
FAP have sympathetic cardiac denervation as assessed by
MIBG imaging despite a preserved LV systolic function
and cardiac perfusion [14]. These findings are in agreement
with the results of Tanaka et al.
In AL (primary) amyloidosis, intractable congestive
heart failure is the most common symptom (occurring in
26–30% of patients), in which interstitial amyloid deposits
are severe enough to cause fatal cardiac dysfunction [15].
In 2002, Hongo et al. were the first to test the hypothesis
that myocardial sympathetic nerve innervation might be
impaired and relates to the presence or absence of clinical
autonomic abnormalities and congestive heart failure in AL
amyloidosis. They examined 25 patients using 123I-MIBG
scintigraphy. The diagnosis of AL amyloidosis was made on
the basis of histological evidence of systemic amyloidosis
and an association with plasma cell dyscrasia and/or
identification of an immunoglobulin light chain in the serum
or urine. Of the 25 patients, 16 were without autonomic
symptoms and 9 had autonomic neuropathy. The H/M ratio
at 3 h (1.53±0.06 vs. 1.29±0.05, p<0.001) and the
myocardial washout ratio (41.5±4.8% vs. 30.8±4.0%,
p<0.001) of MIBG were significantly higher in patients
without autonomic symptoms than in those showing auto-
nomic neuropathy. Patients demonstrating congestive heart
failure (10 of 16 patients without autonomic symptoms and 5
of 9 patients with autonomic neuropathy) showed a
significantly decreased H/M ratio and an increased washout
compared to patients without heart failure. So, in conclusion,
patients with AL amyloidosis and no autonomic dysfunction
showed variable degrees of enhanced cardiac neuronal
activity with presynaptic sympathetic dysfunction. In con-
trast, patients with AL amyloidosis and autonomic neurop-
athy exhibited prominent myocardial denervation with
normal or impaired sympathetic neural function of the heart.
This study showed a heterogeneous myocardial uptake and
turnover of MIBG in patients with AL amyloidosis and the
uptake reflects the presence or absence of congestive heart
failure and cardiac autonomic dysfunction [9].
Another study with the use of 123I-MIBG was performed
by Delahaye et al. in 2006. They conducted a study to
define the outcome of cardiac amyloid involvement after
LT in 31 patients with FAP. Patients were evaluated before
and after LT (24±15 months). Diffuse sympathetic dener-
vation was found on MIBG planar imaging in patients
evaluated before LT and compared with 12 control subjects
(H/M ratio: 1.45±0.29 vs. 1.98±0.35, p<0.001). After LT no
change in sympathetic innervation was found (H/M ratio
after LT: 1.46±0.28), whereas other symptoms (conduction
disturbances, ventricular arrhythmias and LV wall thicken-
ing) showed progression of cardiac amyloid infiltration.
The severity of cardiac sympathetic denervation found in
FAP patients before LT was associated with a neurological
worsening after LT. Therefore, an objective measurement of
cardiac adrenergic innervation, such as that obtained by
MIBG imaging, could help guide the indications for LT in
FAP patients in the early stages of the disease [16].
In most studies, the explanation of the decreased MIBG
uptake was denervation because of the presence of amyloid
deposits. Another cause of the decrease in MIBG uptake
may be a specific involvement of the autonomic system, as
found by Delahaye et al. in 2001. They used the PET tracer
11C-methylquinuclidinyl benzilate (MQNB) and found a
parasympathetic myocardial denervation with a very low
increase in heart rate in patients after atropine injection
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compared with controls, and an upregulation of myocardial
parasympathetic postsynaptic muscarinic receptors in re-
sponse to the presynaptic denervation [17].
Overall, 123I-MIBG seems a good option for objective
evaluation of cardiac sympathetic level and it also seems to




As free fatty acids are the main energy source of the heart
under aerobic fasting conditions, evaluation of myocardial
fatty acid metabolism is useful in understanding patho-
physiological conditions in various heart diseases. The
instability of labelling and the rapid catabolism in cardiac
myocytes through the β oxidative pathway have precluded
the use of 123I-labelled fatty acids for SPECT. An analogue
of free fatty acid, β-methyl-iodophenyl pentadecanoic acid
(BMIPP), is trapped mainly in the triglyceride fractions and
is metabolized more slowly by β oxidation. Because of its
prolonged retention in the myocardium it is suitable for
SPECT imaging [18]. This tracer is generally used for the
evaluation of ischaemic heart disease [19, 20] and cardio-
myopathies [18, 21]. In jeopardized but viable myocardium
BMIPP uptake is less than perfusion (mismatch), and in
nonviable tissue a matched pattern of decreased uptake of
both tracers is visible [22].
For cardiac amyloidosis imaging, the use of 123I-BMIPP is
limited to only one case report. In 1997 Arbab et al. used
various myocardial SPECT agents in a patient with FAP and
suspected myocardial involvement. The 123I-BMIPP study
showed normal fatty acid metabolism, whereas 123I-MIBG
showed a severe impairment of sympathetic function.
This case report suggests that 123I-BMIPP although
useful for evaluating the fatty acid metabolism in the heart
has no role in the evaluation of cardiac amyloidosis.
99mTc (V)-DMSA
99mTc pentavalent dimercaptosuccinic acid (V-DMSA) is a
well-known tumour-seeking agent that accumulates in
medullary thyroid cancer and soft-tissue tumours [23]. Its
mechanism of accumulation is thought to be related to the
structural similarity between pentavalent DMSA and the
phosphate ion PO4
3−, which is avidly taken up by some
cancer cells [24]. Its usefulness in the evaluation of
amyloidosis associated with plasmacytoma (AL type) has
been reported [25, 26]. A disadvantage of pentavalent
DMSA is its physiological uptake in the blood pool, which
explains the very limited use of pentavalent DMSA for the
imaging of amyloid deposits in the heart.
A patient with histologically proven dilated cardiomy-
opathy and a patient with clinically diagnosed cardiomy-
opathy (cardiac amyloidosis was strongly suspected but
was not confirmed) were examined with 99mTc (V)-DMSA
by Ohta et al. 99mTc (V)-DMSA accumulation was clearly
demonstrated in the damaged myocardium. These results
suggested that 99mTc (V)-DMSA could be used as a useful
agent for the evaluation of cardiomyopathy [26].
Another case report was presented by Arbab et al. who
used various SPECT agents in a patient with FAP and
suspected myocardial involvement. They acquired
24-h SPECT images to avoid the blood pool activity in
the heart. The SPECT images showed abnormal uptake of
the tracer in the heart. They suggested that in this patient
either 99mTc-DMSA or 123I-MIBG may be useful to detect
involvement of the heart by the amyloid process [12].
In conclusion, these case reports suggest a role for
pentavalent DMSA in the imaging of cardiac amyloidosis.




Both sestamibi and 201Tl are well-known perfusion tracers.
They perform well in clinical terms, with high sensitivity and
specificity for detecting ischaemia. The use of both tracers
for cardiac amyloid deposition is limited to a couple of case
reports [27, 28] and one rest-redistribution study with 201Tl.
Wechalekar et al. found uptake of a bone-seeking agent
in the heart, suggesting an infiltrative heart disease. 99mTc-
Sestamibi myocardial perfusion scintigraphy showed no
evidence of ischaemia but a low ejection fraction of 28%,
also suggesting the possibility of a muscle disorder. Later,
the patient was diagnosed with cardiac amyloidosis [29].
Kobayashi et al. assessed the changes in cardiac condition
in a patient with biopsy-proven cardiac amyloidosis by
means of SPECT imaging of the heart perfusion with 201Tl
and imaging with a bone-seeking agent on admission and
3 months later. The 201Tl scintigraphy remained almost
unchanged with defects in the septal and posterior wall
regions, the bone-seeking agent showed a marked increase
in myocardial accumulation along with deterioration of
symptoms and signs. The authors considered that 201Tl
defects might reflect myocyte damage due to amyloid
deposits in the myocardium and that the combination of
both a perfusion and a bone-seeking agent is of value in
assessing the degree and distribution of the infiltrative
process of cardiac amyloidosis [30].
Kodama et al. performed rest-redistribution 201Tl myo-
cardial scintigraphy in five patients with biopsy-proven
systemic amyloidosis with cardiac involvement and in 12
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controls. Histopathological study in amyloid heart demon-
strated that myocytes destroyed by deposition of amyloid
protein are present together with viable myocytes. Rapid Tl
washout may be found in amyloid heart as well as in
regions which have a mixture of viable myocytes and scar
tissue in patients with myocardial infarction. They found
that the mean washout rate of the whole heart was higher in
the amyloidosis patients than in the control group. Four of
the five patients in the amyloidosis group showed a very
high washout rate. They also died within a year. They
suggested that the washout rate may reflect the severity of
amyloid deposits in the myocardium and may provide
prognostic information [31].
Altogether, the role for perfusion tracers in evaluating
cardiac amyloidosis is limited.
Amyloid deposits
99mTc-aprotinin
Antiproteases have been detected in amyloid deposits [31].
Although the significance of the accumulation of these
Antiproteases has not been clarified, this observation led to
the investigation of the binding of a protease inhibitor
labelled with 99mTc to amyloid deposits [32]. Aprotinin, a
low molecular weight polypeptide protease inhibitor, was
found to fulfil this criterion. Because of its physiological
uptake in the liver, spleen and kidneys it is only useful in
extraabdominal disease [32].
In 1995, Aprile et al. were the first to evaluate 99mTc-
aprotinin for the imaging of amyloid deposits. They
reviewed the scintigraphic findings in 24 patients with AL
amyloidosis and 1 patient with a hereditary form who were
known to have extraabdominal involvement. Myocardial
accumulation was found in 11 patients. Unfortunately, no
endomyocardial biopsy, the gold standard, was performed
to confirm this finding. The authors concluded that 99mTc-
aprotinin is a potential tracer for the detection of extra-
abdominal AL amyloid deposits, including heart deposits,
which are of paramount prognostic relevance, and that
further investigations are mandatory [33].
Despite these promising results, it was 7 years before
publication of the next article in 2002 by Schaadt et al.
They found focal accumulations of 99mTc-aprotinin in
different organs of 22 patients with a total of 90 lesions,
of which 20 were confirmed by biopsy or autopsy.
Accumulation in the myocardium was seen in 8 patients,
confirmed by biopsy in 4. 99mTc-aprotinin was found to be
a fairly sensitive and specific diagnostic modality in
patients with suspected amyloidosis and is useful for
detection of a wide range of lesions [34].
A recent study was reported by Han et al. in 2007. They
retrospectively reviewed 35 patients who underwent 99mTc-
aprotinin scans for amyloid imaging, of whom 18 had
biopsy-proven amyloidosis (14 AL, 3 AA and 1 ATTR).
The main sites were renal (eight), cardiac (five), lung (one),
oral-nasal (two) and subcutaneous tissue (two). The
remaining 17 patients showed a negative biopsy (eight) or
negative clinical and noninvasive tests (nine) and were
included as a control group. 99mTc-aprotinin uptake in the
region of the myocardium was noted in 5 of the 35 patients
with mild or moderate intensity compared with renal
activity. These five patients had a final diagnosis of cardiac
amyloidosis based on the presence of clinical, echocardio-
graphic and MRI features of infiltrative myocardial disease
and the exclusion of other causes of cardiomyopathy. Four
of these five patients died from cardiac complications
within 2 years of diagnosis. The other 30 patients had no
clinical or echocardiographic evidence of cardiac amyloid-
osis and none showed significant uptake in the heart region.
The authors concluded that 99mTc-aprotinin may help in the
diagnosis of amyloid disease in the heart [35].
In conclusion, these studies suggest a role for 99mTc-aprotinin
in the imaging of cardiac involvement of amyloidosis.
99mTc-labelled phosphate derivatives
Back in 1977 the first study was published that associated
99mTc-diphosphonate with amyloid. This association is
possibly due to high calcium compounds in amyloid, which
suggests the possibility of visualizing calcifications in the
amyloid deposits [36]. Since then, several variants of
phosphate-derivatives have been labelled with 99mTc and
tested, including 99mTc-pyrophosphate (99mTc-PYP), 99mTc-
methylene diphosphonate (MDP) and 99mTc-3,3-diphos-
phono-1,2-propanodicarboxylic acid (DPD) [37].
Many case reports were published in the early 1980s and
later [30, 38–51]. In 1982, Wizenberg et al. investigated a
group of ten patients with tissue-proven amyloidosis using
99mTc-PYP (only two had histologically proven cardiac
amyloidosis). All patients had intense diffuse cardiac
uptake on radionuclide imaging. Other noninvasive tests
suggested cardiomyopathic changes. The authors concluded
that, when combined with noninvasive tests of LV
performance, positive myocardial PYP scanning may
provide a new and useful diagnostic method for the
evaluation of amyloid heart disease [52].
Falk et al. prospectively performed 99mTc-PYP scintig-
raphy in 20 patients with biopsy-proven primary (AL)
amyloidosis. Of these 20 patients, 11 had definitive cardiac
involvement compatible with amyloid cardiomyopathy, 9 of
whom had symptoms of congestive heart failure. In 9 of the
11 patients a diffuse myocardial pyrophosphate uptake was
seen, that did not depend on the presence of congestive
heart failure. But of the 9 remaining patients with biopsy-
proven AL amyloidosis but with a normal echocardiogram,
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only 2 showed uptake in the heart. None of 10 control
patients had a positive myocardial uptake [53]. So 99mTC-
PYP myocardial scanning seems to be a sensitive test for
the diagnosis of cardiac amyloidosis in patients with
congestive heart failure. However, it does not appear to be
of value for the early detection of cardiac involvement in
patients with known primary amyloidosis. So the clinical
relevance remains uncertain.
In 1983, Lee et al. reported a prospective, comparative
study of the efficacy of 99mTc-PYP and 99mTc-MDP in
detecting soft-tissue amyloidosis. The scans were obtained
at 10-day intervals in seven patients with histologically
proven amyloidosis. All seven patients had abnormal
cardiac and/or hepatic 99mTc-PYP uptake, compared to
only four patients who were injected with 99mTc-MDP.
99mTc-PYP was found to be a better scanning agent for soft-
tissue amyloidosis and for cardiac localization of amyloid
[54]. A year later, Eriksson et al. reported less convincing
results for 99mTc-PYP. They examined 12 patients with
familial amyloidosis with polyneuropathy both by cross-
sectional echocardiography and by 99mTc-PYP scintigraphy
to assess involvement of the heart noninvasively. All 12
patients had echocardiographic abnormalities, whereas only
four patients had abnormal myocardial uptake of 99mTc-
PYP. They concluded that a threshold amount of amyloid is
probably required to produce an abnormal scintigram,
although lesions with less amyloid can evidently be
identified by echocardiography [55].
The findings of Lee et al. were also countered by those
of Janssen et al. in 1989. They described the results of
scintigraphy with 99mTc-MDP and 99mTc-PYP as a nonin-
vasive test for the distribution of organ involvement in five
different types of amyloidosis. For whole-body imaging,
99mTc-MDP seemed to be a sensitive noninvasive screening
test to visualize the extent and distribution of organ
involvement in systemic AA and AL amyloidosis. Echo-
cardiography, however, was more sensitive for demonstrat-
ing cardiac involvement than both phosphate-derivatives. In
general, 99mTc-MDP images showed a better contrast than
99mTc-PYP images [56].
Hartmann et al. used a combined first-pass and static
scintigraphy with 99mTc-PYP in seven patients with
myocardial amyloidosis. This diagnosis was made if
patients had biopsy proven amyloidosis in other tissues,
cardiac symptoms and echocardiographic and electrocar-
diographic features compatible with amyloidosis. The static
images showed only insignificant myocardial uptake of the
tracer possibly due to less amyloid fibril. The first-pass
studies, however, revealed reduced systolic function in four
patients and impaired diastolic function in six of the seven
patients. They concluded that 99mTc-PYP scintigraphy is
not useful in screening patients for cardiac involvement in
amyloidosis, but that first-pass studies yield valuable
information about diastolic function impairment [57].
Tanaka et al. performed echocardiography and 123I-MIBG,
201Tl and 99mTc-PYP imaging of the heart in 12 patients
with familial amyloid polyneuropathy and biopsy-proven
cardiac amyloidosis. They found diffuse but mild myocar-
dial uptake of 99mTc-PYP in only 4 of the 12 patients. 123I-
MIBG was found in an earlier stage of cardiac amyloidosis
than 99mTc-PYP [13].
More recently (in 2005), Perugini et al. investigated the
diagnostic accuracy of 99mTc-DPD scintigraphy for the
differentiation of AL and ATTR-type cardiac amyloidosis.
Myocardial uptake was significantly higher in the ATTR
group (n=15) than in the AL group (n=10). Cardiac uptake
was visualized in all the ATTR patients but not in any of
the AL patients. 99mTc-MDP scintigraphy was also
performed in 11 patients with myocardial 99mTc-DPD
uptake. These patients showed no MDP myocardial
uptake. The authors concluded that 99mTc-DPD scanning
is a useful step in the work-up for the differential
diagnosis of ATTR versus AL aetiology in patients with
documented cardiac amyloidosis [58].
Overall, it seems that imaging with 99mTc-labelled phos-
phates has no significant role in detecting myocardial
amyloidosis. The only exception may be, as suggested by
Perugini at al. [58], helping in the differential diagnosis of
ATTR versus AL aetiology [58]. Positive phosphate scan-
ning seems to correlate with high amounts of amyloid fibrils
in the heart, but this occurs at an advanced stage when
clinical symptoms of cardiomyopathy are already apparent.
However, be alert when diffuse myocardial uptake is seen on
a bone scan—it could be cardiac amyloidosis.
67Ga
In the past, 67Ga-citrate was widely used for the detection
of various infections and tumours as a nonspecific agent for
all kinds of diseases. The mechanisms involved in the
concentration of gallium in infections and tumours are still
not fully understood, but in almost all cases the concentra-
tion of gallium correlates with the expression of the
transferrin receptor [59]. With regard to amyloidosis, 67Ga
has very limited value.
In 1979, Braun et al. were the first to describe
diffuse 67Ga uptake in the myocardium [60]. This finding
was confirmed by Montes et al. who found that 67Ga-
citrate scintigraphy exhibited marked myocardial accumu-
lation, but not as high as the diffuse and intense uptake of
99mTc-PYP in the myocardium [61]. Li et al. also found
mild diffuse myocardial uptake of 67Ga-citrate in a patient
with amyloid cardiomyopathy, but also less intense than
the myocardial uptake of 99mTc-PYP [62].
In general, there seems to be no role for 67Ga-citrate in
detecting cardiac amyloidosis.
Eur J Nucl Med Mol Imaging (2009) 36:702–714 709
111In antimyosin antibody
111In-labelled antimyosin antibodies have been shown to
bind specifically to areas of myocardial necrosis. Myosin-
specific antibodies bind to damaged myocardial cells [63].
Previous studies have shown antimyosin uptake in patients
with myocardial infarction, myocarditis, cardiac transplant
rejection and Adriamycin cardiotoxicity [64, 65].
Lekakis et al. reported a case of cardiac amyloidosis
detected by antimyosin imaging [66]. They also prospec-
tively investigated the diagnostic value of antimyosin
scanning in seven patients with biopsy-proven cardiac
amyloidosis. In each patient with cardiac amyloidosis the
antimyosin scan was abnormal with a heart/lung (H/L) ratio
ranging from 2.1 to 3.2, significantly higher than that
observed in six control patients (H/L ratio 1.3–1.6). Diffuse
uptake of antimyosin was observed in all patients with
cardiac amyloidosis. Patients with amyloidosis and conges-
tive heart failure had a higher H/L ratio (2.76±0.30)
compared with patients without clinically evident heart
failure (2.17±0.06). On the basis of these observations the
authors concluded that LV thickening with diffuse myocar-
dial antimyosin uptake is highly suggestive of amyloid
heart disease [67].
Despite these promising results, this is the only article
that was found in the literature concerning antimyosin
uptake in cardiac amyloidosis.
Ventricular function
Radionuclide blood pool ventriculography
Different studies have used radionuclide ventriculography
to compare restrictive cardiomyopathy (in some cases due
to cardiac amyloid) and pericardial constriction. Aroney et
al. found no difference between LV peak filling rates
normalized to end-diastolic volume in patients without
cardiac disease and in patients with pericardial constriction
or restrictive cardiomyopathy [68]. However, Gerson et al.
found a considerably greater LV peak filling rate in patients
with pericardial constriction [69].
Clements et al. showed that patients with cardiac
amyloidosis also had restrictive filling physiology. The
aim of their study was to compare LV systolic and
diastolic function during inspiration and expiration in
four patient groups (patients without cardiac disease,
with severe pulmonary disease, with cardiac amyloid-
osis, and with pericardial constriction). They found some
possible clinical diagnostic implications. First, it may be
possible with radionuclide ventriculography to use
respiratory variations in the LV time to peak filling rate
as a marker of pericardial constriction. Second, LV
filling measurements may be used to distinguish severe
pulmonary disease from cardiac amyloidosis and peri-
cardial constriction [70].
Hongo et al. assessed LV diastolic findings in 17 patients
with familial amyloid polyneuropathy and in 20 normal
subjects by radionuclide angiography. Peak filling rate was
significantly lower and time to peak filling significantly
higher in patients than in normal subjects. Most patients
had no clinical evidence of heart disease, a normal
ventricular wall thickness and a normal ejection fraction,
but an abnormality in diastolic filling. Thus, abnormal
diastolic filling can be seen even in the early stages of
familial amyloid polyneuropathy and may be related to
myocardial amyloid deposition [71].
Discussion
Amyloidosis is a systemic disease that can affect multiple
organs and therefore has a poor prognosis. Different types
of amyloidosis are related to underlying disease and to
deposition in various organs. Several imaging modalities
have been proposed for the identification of specific organ
involvement and risk stratification. In particular, the added
value of identification of cardiac involvement is very high,
because of the high rates of arrhythmias, the quick
deterioration in cardiac dysfunction and sudden death.
Diagnostic imaging of the severity of cardiac amyloidosis
is important in the decision making concerning ICD
implants or heart transplantation. Therefore, reliable and
early detection of cardiac involvement of amyloidosis is
important. In this review, we tried to identify all nuclear
imaging modalities for the detection of cardiac amyloidosis.
Nuclear imaging modalities identify pathophysiological
activity which makes it possible to identify organs at risk
at an early stage. Another added value of nuclear imaging
modalities is the possibility for quantification.
A stepwise approach to diagnosis of and therapy for
systemic amyloidosis was presented by Hazenberg et al. [2].
The heart can be examined with electrocardiography (signs of
low voltage and pseudoanteroseptal infarction), chest radiog-
raphy (normal sized heart despite signs of cardiac failure),
echocardiography (thickness of septum and ventricular walls),
and MUGA scan (LV ejection fraction). But these examina-
tions are all nonspecific for cardiac amyloid involvement.
Two biochemical markers are of importance in cardiac
amyloidosis. NT-proBNP (the N-terminal pro-brain natri-
uretic peptide) appears to be a sensitive marker of
myocardial dysfunction and a powerful prognostic deter-
minant in AL amyloidosis. Heart involvement was estimat-
ed on the basis of clinical signs, electrocardiography and
echocardiography [72]. Another study also concluded that
determining levels of circulating biomarkers (NT-proBNP
and cardiac troponins) may be a powerful tool for staging
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patients with AL, especially those patients undergoing
peripheral blood stem cell transplantation [73].
For specific evaluation systemic amyloidosis, serum
amyloid P component (SAP) scintigraphy is a technique that
has been developed in London for specific evaluation of
amyloidosis [74–77] and is extensively used in our hospital.
All amyloid deposits contain SAP, a glycoprotein that binds
in a calcium-dependent way to all amyloid deposits
independently of the protein of origin. SAP is labelled with
123I and shows specific uptake in the liver, spleen, kidneys,
adrenals, bone marrow and joints (for example, see Fig. 2).
However, the myocardium does not show specific uptake,
probably due to the combination of high background activity
of tracer still present in the blood pool and decreased
permeability of this tracer in cardiac tissue. Therefore, 123I-
SAP scintigraphy is very useful for systemic amyloidosis,
but not for identifying cardiac involvement.
With regard to the optimal imaging modality to visualize
cardiac amyloid involvement, different imaging methods are
available each with a different physiological mechanism. It
seems clear that imaging with perfusion tracers (99mTc-
sestamibi and 201Tl) and evaluation of LV function (radio-
nuclide ventriculography) is not the best method, because of
their very low specificity. Imaging the metabolism of free
fatty acids with 123I-BMIPP also has no role in the
evaluation of cardiac amyloidosis (limited experience, better
results with other radionuclides). Another tracer of metabo-
lism, 99mTc (V)-DMSA has a high physiological uptake in
the blood pool and is therefore of very limited use for
amyloid depositions in the heart. The best results can be
found with radiopharmaceuticals that image amyloid depos-
its or indirectly by imaging myocardial neuropathy.
Aprotinin labelled with 99mTc provides an imaging
method for amyloid deposits. Because of physiological
uptake in the liver, spleen and kidneys it is only useful in
extraabdominal disease, such as cardiac depositions. A
limited number of studies have been performed with this
tracer, but all conclude that 99mTc-aprotinin can be helpful
in the diagnosis of amyloid heart disease. Different
phosphate derivatives (PYP, MDP, DPD) labelled with
99mTc seem valuable for detecting cardiac involvement of
amyloidosis, but a certain amount of amyloid is necessary.
There seems to be no role for this approach in the early
detection of cardiac amyloidosis, but it may play a role in
the differential diagnosis of ATTR versus AL aetiology in
patients with documented cardiac amyloidosis [58]. There
is only a limited role for 67Ga for detection amyloid
depositions in the heart with no advantages compared to
other tracers. One study has shown promising results for
111In antimyosin antibody imaging [65]. More studies have
to be performed to determine the exact role of this
antimyosin antibody in imaging. To date, the best option
for imaging amyloid deposits seems to be with 99mTc-
aprotinin. But all the tracers mentioned previously do not
have a very high sensitivity.
The best results we found in the literature are related to
the imaging of myocardial innervation by 123I-MIBG.
Fig. 2 Serum amyloid P component scintigraphy: a normal patient; b
intense uptake in the liver and spleen in a patient with AL
amyloidosis; c uptake in the spleen and kidney in a patient with AA
amyloidosis (Hazenberg et al.)
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MIBG is retained in sympathetic nerve endings, and the
localization of MIBG relates to the presence of sympathetic
nerves. Myocardial defects in MIBG activity seem to
correlate with impaired cardiac sympathetic nerve endings
due to amyloid deposits. This can be identified very early in
cardiac amyloidosis and shows better results than with
other tracers. The clinical severity of disease correlates with
a decrease in MIBG uptake. Overall, 123I-MIBG is a good
option for objective evaluation of cardiac sympathetic level
and seems to have an important role in the measurement of
amyloid myocardial infiltration.
None of the tracers have been used in the follow-up of
disease. We could not find clinical studies concerning the
correlation of tracer with the prognosis of disease, but it seems
that the amount of decrease in MIBG activity correlates with
the severity of amyloid involvement and therefore a worse
prognosis. High uptake of Tc-labelled phosphates in the heart
correlates with high amounts of amyloid fibrils in the heart
and therefore with an advanced stage.
All of the above-mentioned tracers are SPECT tracers. In
general, PET tracers will provide absolute quantification
and definitely better resolution than SPECT tracers and
hence there may be an advantage in using PET tracers for
the evaluation of amyloidosis. There are a few PET tracers
now available, but none of them is very specific for
amyloidosis. 18F-FDG, the most widely used PET tracer,
is not suitable for evaluating systemic amyloidosis. There
are some case reports of positive FDG-PET findings in
pulmonary amyloidosis, but with very low specificity [78].
Because of the physiological uptake of FDG in the heart, it
is not used in cardiac amyloidosis. 11C-m-hydroxyephe-
drine is useful for sympathetic innervation quantification of
the heart (usually in diabetic patients), but is not used for
imaging cardiac amyloidosis. 11C-Pittsburgh compound-B
(PiB) is used with very good results for imaging brain
amyloid in Alzheimer’s disease by binding to amyloid-β
deposits [79, 80], but this β type is specific for the brain
and not deposited elsewhere in the body. It is not the tracer
of choice for imaging cardiac amyloidosis.
In conclusion, the most validated and most accurate but
indirect imaging method in nuclear medicine for the
evaluation of amyloid myocardial infiltration is 123I-MIBG.
PET tracers, despite the big advantages of absolute
quantification and higher resolution, are not used for the
evaluation of cardiac amyloidosis. This may be an
additional clinical challenge in this era of PET proliferation.
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